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Abstract Ataxia with oculomotor apraxia type 2 (AOA2) is
caused by a diversity of mutations within the coding region
of the senataxin gene. Recently, rare noncoding senataxin
mutations affecting RNA processing have been identified in
AOA2. Here, we report the case of an 18-year-old woman,
with classic clinical features of AOA2, who was found to
harbor a mutation within senataxin intron 16. This mutation
disrupts the local 5′ splice site architecture via a novel
intronic frameshift mechanism, causing skipping of exon 16
with predicted disruption of the conserved DNA/RNA
helicase domain. RNA processing mutations expand the
growing complexity of pathogenic senataxin mutations.
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Introduction
Ataxia with oculomotor apraxia type 2 (AOA2) is an
autosomal recessive hereditary ataxia caused by mutation of
the senataxin gene (SETX) on chromosome 9q34 [1–4]. The
disease is characterized primarily by vermian cerebellar
atrophy with prominent gait ataxia, a peripheral sensorimotor
neuropathy, areflexia, and elevated levels of α-fetoprotein
[1–3, 5–7]. Eye findings commonly include saccadic ocular
pursuit with nystagmus; however, despite the name, oculo-
motor apraxia is not found in many patients [1–3, 5–7].
AOA2 is thought to be one of the most common autosomal
recessive ataxias after Friedreich’s ataxia [2, 4, 7]. The
clinical phenotype associated with SETX mutations also has
an interesting, although rare, variability. Notably, an autoso-
mal dominant phenotype of juvenile-onset amyotrophic
lateral sclerosis (ALS4) has been associated with mutations
in this gene distinct from those which cause AOA2 [8–10].
The senataxin gene is quite polymorphic, and a variety
of homozygous and compound heterozygous coding muta-
tions have been reported which cause AOA2 including
missense [1, 3, 5–7, 9, 11, 12], nonsense [1, 3, 6, 7, 13],
frameshift [1, 3, 5–7, 12, 14–16], gene rearrangement [5],
deletion [7] or duplication [14]. One coding mutation at the
terminus of exon 15 has also been reported to disrupt RNA
splicing [16]. In contrast to these many coding mutations,
only two pathogenic noncoding mutations have been
reported which result in AOA2 [5, 7, 17]. Here, we report
a patient from a large consanguineous family who was
found to possess a novel homozygous mutation in intron 16
which results in aberrant splicing of the SETX pre-mRNA
and clinical AOA2.
Case Report
The patient is an 18-year-old woman who presented with
complaints of imbalance, falls, and difficulty walking.
Onset was at age 14, and course was slowly progressive.
Past medical history included polycystic ovarian syndrome
diagnosed at age 16. Neurological examination was notable
for a mild appendicular and gait ataxia, slowing of vertical
saccades, and a mild dysarthria. Deep tendon reflexes were
absent, and there was reduced sensation in the feet to
pinprick, temperature, and vibration, which was most
severely impaired. There was no oculomotor apraxia.
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Laboratory studies were notable for elevated alpha-
fetoprotein (7.8 ng/mL, normal less than 6.7 ng/mL). Normal
studies included serum electrolytes, renal function testing,
liver function testing, vitamin B12, folate, homocysteine,
methylmalonic acid, copper, ceruloplasmin, creatinine
kinase, thyroid function studies, serum protein electropho-
resis with immunofixation, erythrocyte sedimentation rate,
antinuclear antibodies, and tests for GAD-65, thyroglobulin,
gliadin, and Yo autoantibodies. Rapid plasma reagin and
HTLV I/II screening were nonreactive. A sensorimotor
neuropathy autoantibody panel (Athena Diagnostics, Inc.)
was negative. Previous tests for follicle-stimulating hor-
mone, luteinizing hormone, prolactin, estradiol, progester-
one, testosterone, and cortisol were normal. Magnetic
resonance imaging showed cerebellar atrophy. A nerve
conduction study showed a sensorimotor axonal neuropathy.
Echocardiogram was normal. The family is from Pakistan,
and consanguinity was reported (Fig. 1), but there were no
other individuals in the family identified with ataxia.
Genetic testing included normal sequencing of the
aprataxin gene (APTX) and the alpha-tocopherol transfer
protein gene (TTPA). No repeat expansions were detected in
the frataxin gene (FXN). Sequencing of the senataxin gene
revealed a homozygous insertion of a thymidine at position
+2 of intron 16 (IVS16+2insT; Fig. 1).
Materials and Methods
Genomic DNA was prepared from blood using Autopure
LS (Qiagen) according to the manufacturer’s instructions.
Sequencing of senataxin coding exons and the neighboring
intronic regions was performed from genomic DNA using a
3730 DNA Analyzer (Applied Biosystems). Primer sequen-
ces utilized were as described in Criscuolo et al. [5].
Total RNA from peripheral blood was extracted using the
PAXgene Blood RNA Kit (Qiagen) per the manufacturer’s
instructions. RNA quality control was performed using an
Agilent Bioanalyzer 2100 (Agilent Technologies). Human
fetal and adult brain were obtained from the NICHD Brain
and Tissue Bank for Developmental Disorders (University of
Maryland, Baltimore, MD, USA). Total RNA was obtained
Fig. 1. A homozygous intronic
point mutation in the senataxin
gene in a patient with ataxia
with oculomotor apraxia type 2.
The pedigree of the family
described in this report is
shown. The affected proband is
indicated by a filled circle. No
other individuals were reported
to have ataxia. A schematic of
the senataxin exon/intron
junction is shown for exon 16
with the corresponding results of
DNA sequencing for the
proband. Intronic sequence is
denoted by a dashed underline.
The identified mutation, a thy-
midine insertion at position +2
of the intron, is indicated by an
arrow. The consensus sequence
of a 5′ splice site is shown above
the patient’s sequence
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using an RNeasy Mini Kit (Qiagen) per the manufacturer’s
instructions. Reverse transcription (RT) was performed
using total RNA primed with oligo-dT in the SuperScript
III First-Strand Synthesis System (Invitrogen). Polymerase
chain reaction (PCR) was performed using a high-fidelity
proofreading polymerase (Accuprime Pfx, Invitrogen) and
approximately 10–50 ng of cDNA. PCR cycle settings were
94°C for 30 s, 55°C for 30 s, and 72°C for 30–45 s for a
total of 35–40 cycles. For nested PCR, dilutions of the
initial PCR reaction (ranging from 0.08% to 6%) were used
in a second reaction with primers internal to the first set. All
PCR products were confirmed by sequencing as above. All
primer sequences are available on request. Gel images were
captured using a BioSpectrum AC Imaging System (UVP).
Exon numbering is based on the 26 exons known to be
expressed by the SETX gene (NM_015046). The SETX
coding region is represented by exons 3–26 (with exons
14–26 encoding the DNA/RNA helicase domain). The
novel exon reported here is designated exon 25b to match
with current exon numbering.
Results
Sequencing of intron 16 in this patient identified a
homozygous insertion of one base pair, thymidine (T), at
position +2 of intron 16 (Fig. 1). The patient’s mother was
found to be heterozygous for this mutation (data not
shown). The father was not available for testing so we
cannot determine if the second mutation was inherited (as
predicted by the pedigree) or arose de novo.
As senataxin is expressed in lymphoblasts, we were able
to investigate the functional consequences of this mutation,
which we hypothesized would disrupt normal RNA splicing.
Total RNA from the proband’s mother was converted to
cDNA for use in nested RT-PCR with primers spanning
exons 15 and 17 of senataxin. This demonstrated the
presence of the expected band representing exons 15–17 as
well an additional band corresponding to the skipping of
exon 16 (Fig. 2). In the patient, only the misspliced product
was detected (Fig. 2). The new protein product generated
from this splicing event is predicted to lack a functional
DNA/RNA helicase domain.
Previously, senataxin has not been thought to undergo
significant alternative splicing [9]. However, review of the
Alternative Splicing and Transcript Diversity database [18]
identifies a total of four additional human senataxin
transcripts supported by expressed sequence tag (EST) data
which include the DNA/RNA helicase domain (data not
shown), and therefore may potentially have functional
significance (see “Discussion”). The largest alternate
transcript includes an additional 3′ exon (which we term
exon 25b) which adds 29 amino acids at the C-terminal
portion of the DNA/RNA helicase domain after position
2429 (Fig. 3). The remaining isoforms are smaller due to
utilization of alternative transcription start sites (in exon 10)
and/or alternative splicing involving exon 25b or exon 24
(which removes 33 amino acids in the DNA/RNA helicase
domain after position 2366; Fig. 3). We find support for
these splicing patterns from multiple unique ESTs (Fig. 3).
Furthermore, using RT-PCR, we detected transcripts fea-
turing the alternative use of both exon 25b and exon 24 in
both human fetal and adult brain (Fig. 3).
Discussion
Senataxin is a large 2,677 amino acid protein whose function
still remains relatively unknown. Although multiple regions
of the protein appear to be important for disease, an attractive
target is the conserved C-terminal DNA/RNA helicase
domain found at amino acids 1931–2456 (encoded by exons
14–26) [1, 8, 12]. Mutations that alter or disrupt this
domain cause AOA2, presumably through a loss of
function [1, 3, 8, 9, 12]. Recent studies strengthen the
relevance of the DNA/RNA helicase domain by providing
evidence for a role of senataxin in DNA damage response
[17] and potential roles in transcription and RNA process-
ing based on work with the yeast ortholog [19].
In this report, we identified a novel intronic mutation
resulting in aberrant splicing of the SETX mRNA in a
patient with clinical AOA2. Three previous mutations that
affect splicing of the senataxin pre-mRNA have been
reported [5, 7, 16, 17] (Fig. 2). One of these results from
a G>A transition at c.6106, the last nucleotide of exon 15,
resulting in skipping of the exon [16], with a frameshift
mutation and truncation at amino acid 1989. The other two
mutations are intronic—one, IVS25+5G>A, results in skip-
ping of exon 25 leading to a frameshift [5, 17] with protein
truncation at amino acid 2408, and another, IVS19+5G>T,
which skips exon 19, resulting in an in-frame deletion of
amino acids 2133–2182 [7]. The mutation reported here,
IVS16+2T, results in skipping of exon 16 (Fig. 2). The
mechanism of this mutation is novel relative to the other
known SETX splicing mutations, as the inserted T at
position +2 induces an intronic frameshift in the neighbor-
hood of the intron 16 5′ splice site sequence which would be
predicted to dramatically reduce splice site utilization [20].
The resultant skipping of exon 16 identified in Fig. 2 would
result in the in-frame replacement of amino acids 2036–2070
with a glutamic acid residue. Interestingly, all these RNA
processing mutations affect the DNA/RNA helicase domain,
further implicating the importance of this region in AOA2
pathogenesis [12].
Additionally, it is also of considerable interest that
despite the wide variety of mutations seen in AOA2, only
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a few distinct heterozygous missense mutations have thus
far been identified in motor neuron disease [8–10]. This
observation would be consistent with the proposed gain-of-
function hypothesis in ALS4. It is worth noting that one of
the SETX splicing mutations seen in AOA2, IVS19+5 G>T
[7], removes residue 2136 which has been detected as
mutated in cases of ALS4 (R2136H) [8, 9]. As the patients
clinically have AOA2 [7], this demonstrates that deletion of
this residue is insufficient to produce a motor neuron
phenotype even when homozygous, suggesting that an
intact DNA/RNA helicase domain is required for the
development of ALS4.
In addition to AOA2, the patient reported here also
carries a diagnosis of polycystic ovarian syndrome. This
may be relevant, as early menopause and premature ovarian
failure have been reported in other cases of AOA2 [2, 5,
13], suggesting a germ line effect, at least in affected
women. While the genetic risk for polycystic ovarian
syndrome is complex [21], given the above findings, it is
interesting to speculate that senataxin mutations (or perhaps
a specific subset thereof) may alter the risk of this
associated condition in affected women.
Finally, we have demonstrated the presence of alterna-
tively spliced senataxin transcripts in human fetal and adult
brain. It is of considerable interest that the variability in
these transcripts resides in the C-terminal portion of DNA/
RNA helicase domain. The role of these (and potentially
other) isoforms of senataxin in endogenous function and in
the pathogenesis of AOA2 and ALS4 is an important new
area of study. In conjunction with the known patient data,
Fig. 2. Aberrant splicing of
senataxin in patients with
AOA2. a Total peripheral blood
RNA from the proband (P) and
her mother (M) as well as an
unrelated normal control
individual (C) was used for
RT-PCR with primers
amplifying across exons 15 and
17 (black arrows) followed by
internal nested primers (gray
arrows). Exons are shown in
genomic context with intronic
sequences indicated by dashed
lines. The detected spliced
products (shown) either include
or exclude exon 16 (291 or 189
base pairs, respectively). HPRT
was amplified as a positive
control (489 base pair product).
Size markers are indicated in
base pairs. The predicted effect
on senataxin protein is shown
graphically with the DNA/RNA
helicase domain (aa 1931–2456)
indicated by a black line and an
in-frame deletion shown by the
dashed segment. b Previously
published senataxin mutations
which affect RNA splicing are
shown with the corresponding
mutation (arrow) in the genomic
context. The abnormal splicing
event is indicated by boxes, and
the resulting effect on the
protein is shown graphically as
in part a. Protein truncation is
shown by a dashed line
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Fig. 3. Alternative splicing of the senataxin gene. a The genomic
structure of the senataxin gene is shown. Exons are boxed and introns
are shown by a dashed line. Predicted transcription start sites are
indicated by arrows. Suspected alternative exons are indicated by
dotted boxes and the alternative splicing pattern is shown by a black
line. The region of exons 23–26 is expanded to highlight the details of
this alternative splicing. Supporting data from ESTs is shown in the
table. Data compiled from the Alternative Splicing and Transcript
Diversity database and the National Center for Biotechnology
Information EST database. The number of ESTs with at least one
splice junction represented is shown with the number of ESTs
covering both splice junctions shown in parentheses. For events
involving multiple exons, the number of transcripts including both
junctions is shown for each exon. Asterisk: the pattern excluding exon
25b is the established pattern of senataxin splicing in the literature. b
Confirmation of senataxin alternative splicing in human fetal and adult
brain. Total RNA from human fetal (upper panel) or adult (lower
panel) brain was used for RT-PCR with primers (black arrows)
designed to amplify the suspected alternative splice products shown in
the diagram. HPRT (489 bp) was used as a positive control. Products
not detected in the initial PCR reaction were re-evaluated using a
nested PCR reaction (underlined lanes) to detect lower abundance
messages. Due to the size of the senataxin message, product 1517 can
require nested PCR (gray arrows) to detect with oligo-dT primed
cDNA. All PCR products were confirmed by sequencing. Molecular
weight markers are indicated in base pairs. Asterisk: these additional
bands are PCR artifacts (data not shown) produced by mispriming of
the primer used to detect the exon 23—exon 25 splice junction
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these observations highlight RNA processing errors as a
newly recognized class of SETX mutations in AOA2 and
adds to the growing diversity of pathogenic mutations seen
in this gene.
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